Boston Scientific launched the AVANT GUARD trial in 2023 to assess FARAPULSE PFA System's efficacy as a primary treatment for persistent atrial fibrillation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Boston Scientific launched the AVANT GUARD trial in 2023 to assess FARAPULSE PFA System's efficacy as a primary treatment for persistent atrial fibrillation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.